Research Triangle Park, NC, August 13, 2005 - - PhytoHealth Corporation in Taiwan has signed an agreement with Jenken to license Jenken's lead compound for treating chronic liver diseases. The agreement includes upfront and milestone payments plus royalties.

At the same time, Jenken sublicensed a compound from PhytoHealth Corporation for treating motion sickness. This compound has been marketed in China and is currently in Phase 3 clinical trials in Taiwan.

About Jenken Biosciences
Jenken Biosciences, Inc. is an early-stage, specialty pharmaceutical company dedicated to "repurposing" (finding new therapeutic uses for) off-patent, approved drugs. Jenken is currently repurposing two marketed drugs which could revolutionize the treatment of diseases associated with chronic organ inflammation. Jenken's drug development strategy is to reduce time-to-market and to lower risk and development costs by re-profiling approved drugs and their analogs or metabolites. Jenken was recently selected as one of only nine early-stage companies from across the East Coast to present at CED's Opportunity 2006 Conference scheduled for December 4-5, 2006, in Wilmington, North Carolina. Jenken will also be presenting at The 2006 Venture Summit on November 28, 2006, in Burlington, Massachusetts.

FOR MORE INFORMATION, CONTACT:

Barry Buzogany
Chief Executive Officer
919-765-0032
bbuzogany@jenkenbio.com